Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFRMakoto Maemondo, Toshihiro Nukiwa, Akira Inoue et al.|New England Journal of Medicine|2010Cited by 5.6k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trialEnriqueta Felip, Heather A. Wakelee, Nasser K. Altorki et al.|The Lancet|2021Cited by 1.5k
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trialHaruhiro Saito, Makoto Maemondo, Tatsuro Fukuhara et al.|The Lancet Oncology|2019Cited by 636
Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 StudyYukio Hosomi, Satoshi Morita, Shunichi Sugawara et al.|Journal of Clinical Oncology|2019Cited by 483
Randomized Phase II Trial Comparing Amrubicin With Topotecan in Patients With Previously Treated Small-Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 0402Akira Inoue, Toshihiro Nukiwa, Shunichi Sugawara et al.|Journal of Clinical Oncology|2008Cited by 235